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The Veterans Affair's (VA) is the nation's largest integrated healthcare system, providing care to 12 over 9 million Veterans in over 140 medical centers and 1200 outpatient clinics throughout the 
4
We identified high rates of antimicrobial resistance to several commonly used E. coli UTI 5 treatment options. The overall rate of fluoroquinolone resistance using NHSN methods was 6 34.3%, with resistance reaching almost 50% among inpatients and 30% for outpatients similar to 
10
Our study also demonstrated trimethoprim/sulfamethoxazole resistance approaching 30%. and these changes may have been applied at different times by individual laboratories. As such,
8
we applied the 2014 CLSI breakpoints to our data when MIC data was available. Finally, the 9 generalizability of our results may be limited to the VA population.
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In conclusion, among almost 300,000 urinary E. coli isolates collected from a predominately male
12
VA outpatient population, resistance to fluoroquinolones and trimethoprim/sulfamethoxazole Affairs, and has received research funding from Merck (Cubist).
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Antipseudomonal penicillin/ beta-lactamase inhibitor category included piperacillin/tazobactam 4 and ticarcillin/clavulanic acid.
5
Carbapenem category included imipenem, meropenem, doripenem, and ertapenem.
6
Extended spectrum cephalosporin category included ceftriaxone, ceftazidime, cefotaxime, and 7 cefepime.
8
Fluoroquinolone category included levofloxacin and ciprofloxacin. Aminoglycoside category included amikacin, gentamicin, and tobramycin.
6
Antipseudomonal penicillin/ beta-lactamase inhibitor category included piperacillin/tazobactam 7 and ticarcillin/clavulanic acid.
8
9
Extended spectrum cephalosporin category included ceftriaxone, ceftazidime, cefotaxime, and 10 cefepime.
11
Fluoroquinolone category included levofloxacin and ciprofloxacin.
12
Amoxicillin or ampicillin/ beta-lacamase/beta-lactamase inhibitor category included 
11
Data are % non-susceptible (total number of isolates tested). Not every antibiotic category tested for every isolate tested.
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